What equity awards did SOPH Chief Medical Officer Philippe Menu receive?

Philippe Menu received a stock option for 164,671 ordinary shares at $5.04 per share and 112,936 restricted stock units. Both awards were granted as equity compensation and are subject to multi-year vesting schedules tied to continued service with SOPHiA GENETICS SA.

How many SOPH ordinary shares does Philippe Menu own after these grants?

After the reported equity awards, Philippe Menu beneficially owns 286,552 ordinary shares. This figure replaces a previously misreported amount of 112,936 shares and reflects his corrected direct ownership following the April 2, 2026 transactions.

SOPHiA GENETICS (SOPH) CMO awarded options and RSUs, ownership corrected

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

4/A

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported equity compensation grants consisting of options and restricted stock units tied to ordinary shares. He received a share option covering 164,671 ordinary shares at an exercise price of $5.04 per share, vesting 25% on April 2, 2027 and monthly through April 2, 2030. He also received 112,936 RSUs, each representing one ordinary share, vesting 25% on April 2, 2027 and the remaining 75% in equal quarterly installments through April 2, 2030, subject to continued service. Following these grants, his beneficial ownership of ordinary shares was corrected to 286,552 shares due to an earlier inadvertent reporting error.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Menu Philippe

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	164,671	$0.00	--
Grant/Award	Ordinary Shares	112,936	$0.00	--

Holdings After Transaction: Share Option (Right to Buy) — 164,671 shares (Direct); Ordinary Shares — 286,552 shares (Direct)

Footnotes (1)

Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030. This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 112,936 ordinary shares due to an inadvertent error. The correct amount is 286,552 ordinary shares. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

Key Figures

Stock option grant: 164,671 options Option exercise price: $5.04 per share RSU grant size: 112,936 RSUs +4 more

7 metrics

Stock option grant 164,671 options Right to buy ordinary shares at $5.04 per share granted April 2, 2026

Option exercise price $5.04 per share Exercise price for 164,671-share option grant

RSU grant size 112,936 RSUs Each RSU represents one ordinary share, granted April 2, 2026

Corrected share ownership 286,552 shares Ordinary shares beneficially owned following transactions

RSU vesting start April 2, 2027 25% of RSUs vest on this date, remainder quarterly to April 2, 2030

Option vesting start April 2, 2027 25% of underlying shares vest, then monthly to April 2, 2030

Option expiration date April 2, 2036 Expiration for the 164,671-share option grant

Key Terms

restricted stock unit ("RSU"), 2021 Equity Incentive Plan, vest, share option, +1 more

5 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan."

2021 Equity Incentive Plan financial

"RSU grant made under the Issuer's 2021 Equity Incentive Plan."

vest financial

"25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

beneficially owned financial

"correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction)."

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

04/08/2026 - 08:47 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Menu Philippe

(Last)

(First)

(Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE

1180

(City)

(State)

(Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
04/03/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	04/02/2026		A		112,936⁽¹⁾	A	$0	286,552⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option (Right to Buy)	$5.04	04/02/2026		A		164,671		⁽³⁾	04/02/2036	Ordinary Shares	164,671	$0	164,671	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

2. This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 112,936 ordinary shares due to an inadvertent error. The correct amount is 286,552 ordinary shares.

3. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Philippe Menu	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

How do the new RSUs for SOPH’s Chief Medical Officer vest?

The 112,936 RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. Each vested RSU entitles Philippe Menu to receive one ordinary share, provided he continues serving the company.

What is the vesting schedule for Philippe Menu’s new SOPH stock options?

The option for 164,671 ordinary shares vests 25% on April 2, 2027, then in equal monthly installments through April 2, 2030. Once vested, the option is exercisable at an exercise price of $5.04 per ordinary share, subject to plan terms.

Why did SOPHiA GENETICS file an amended Form 4/A for SOPH?

The amended Form 4/A corrects the amount of ordinary shares beneficially owned after the reported transaction. A prior filing showed 112,936 shares due to an inadvertent error, while the correct post-transaction ownership is 286,552 ordinary shares held by Philippe Menu.